COMMUNIQUÉS West-GlobeNewswire

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
14/10/2026
-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non-human primate [...]
Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome
14/10/2026
FDA’s Rare Disease Evidence Principles ( RDEP) process aims to provide greater speed and predictability in the review of therapies for rare diseases with significant unmet medical need Acceptance enables engagement with [...]
Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer
14/10/2026
Dr. O’Malley brings deep immunology clinical development expertise, with previous leadership roles at CRISPR Therapeutics and Sanofi Appointment follows Matchpoint’s recent $150M Series B financing to advance pipeline [...]
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
14/10/2026
-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- [...]
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
14/10/2026
FLINTLOCK Phase 2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in adults aged 18-65 years with Long COVID or Post-Vaccination [...]
Purespring Therapeutics to present new data on pipeline progress in Alport Syndrome at the American Society of Nephrology (ASN) Kidney Week 2026
14/10/2026
New preclinical data demonstrates PS-003 restores the key collagen protein missing in X-linked Alport Syndrome (XLAS) and is presented alongside findings from one of the largest genetic studies of Alport Syndrome to [...]
Glass House Brands Receives Good Agricultural and Collection Practice (GACP) Certifications
14/10/2026
GACP Certification from Perry Johnson Supports Pathway to International Markets This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated June 10, 2026, to [...]
TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
14/10/2026
TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iMRI”) Symposium in [...]
Rhea’s Factory Partners with Niagara Bottling on Industrial Validation of Enzymatic PET Recycling Through U.S. Department of Energy Program
14/10/2026
One of the first industrial deployments of enzymatic PET recycling in the world will validate Rhea’s Factory’s AI-designed enzymes and end-to-end process as a complement to Niagara Bottling’s mechanical recycling [...]
Discovery Health expanded access to mental healthcare for 22,000 members in one year, with better outcomes and lower hospital costs
14/10/2026
A fully funded digital mental health benefit integrated into Discovery Health’s existing care pathways and member app reached 22,000 member activations in its first 12 months, with 90% user satisfaction, clinically [...]
Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026
14/10/2026
New Clinical Studies Validate BVA ™ Technology in High-Acuity Heart Failure Populations to Enhance Care OAK RIDGE, TN, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume [...]
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
14/10/2026
SAN DIEGO and SUZHOU, China, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based [...]
BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
14/10/2026
CARSON CITY, Nev., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases [...]
Lifeward’s ReWalk® Personal Exoskeleton Demonstrates Sustained Long-Term Home Use and Patient Satisfaction in Latest Independent Peer-Reviewed Study
14/10/2026
Study shows ReWalk can be used for years and provides measurable walking performance for people with chronic paraplegia ReWalk was use d for a median of 33 months, with no reported falls or exoskeleton-related fractures [...]
Bluesight Launches Prism Assistant in PrivacyPro, Bringing AI-Powered Investigations to Patient Privacy Teams
14/10/2026
Alexandria, VA,, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Prism Assistant helps privacy teams accelerate investigations, reporting, and analysis – while keeping sensitive patient access data secure. Bluesight, the leader in [...]
iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch
14/10/2026
NASHVILLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced the appointment of Donnie Purto as Senior Vice President of Sales to lead the company’s [...]
GeneCentric Announces Oral Presentation at ASHG 2026 Highlighting Fragmentomics-based ExpressCT™ Liquid Biopsy Technology
14/10/2026
DURHAM, N.C., Oct. 14, 2026 (GLOBE NEWSWIRE) -- GeneCentric , a company making precision medicine more precise by bringing gene expression biology to liquid biopsy, today announced that it will present at the American [...]
Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research
14/10/2026
SYDNEY, AUSTRALIA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and [...]
Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
14/10/2026
BRISBANE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional [...]

Pages